Loading...
Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes
OBJECTIVE: Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week, randomized, double-blind, multicenter trial, evaluated the overall safety and cardiovascular safety of this novel therapy...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Diabetes Association
2010
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2890350/ https://ncbi.nlm.nih.gov/pubmed/20332352 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc09-2009 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|